Cargando…

Co-Spray Dried Nafamostat Mesylate with Lecithin and Mannitol as Respirable Microparticles for Targeted Pulmonary Delivery: Pharmacokinetics and Lung Distribution in Rats

Coronavirus disease 2019 (COVID-19), caused by a new strain of coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly worldwide. Nafamostat mesylate (NFM) suppresses transmembrane serine protease 2 and SARS-CoV-2 S protein-mediated fusion. In this study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Ji-Hyun, Kim, Young-Jin, Yang, Min-Seok, Shin, Dae Hwan, Kim, Dong-Wook, Park, Il Yeong, Park, Chun-Woong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468663/ https://www.ncbi.nlm.nih.gov/pubmed/34575594 http://dx.doi.org/10.3390/pharmaceutics13091519

Ejemplares similares

In vivo pharmacokinetic and pharmacodynamic study of co-spray-dried inhalable pirfenidone microparticles in rats
por: Kang, Ji-Hyun, et al.
Publicado: (2022)

Fatal anaphylaxis Due to Nafamostat Mesylate During Hemodialysis
por: Kim, Joo-Hee, et al.
Publicado: (2021)

Nafamostat mesylate attenuates the pathophysiologic sequelae of neurovascular ischemia
por: Ghali, George Zaki, et al.
Publicado: (2020)

Cardiopulmonary arrest caused by nafamostat mesylate during hemodialysis
por: Shioya, Nobuki, et al.
Publicado: (2022)

Encapsulation of Alcohol Dehydrogenase in Mannitol by Spray Drying
por: Shiga, Hirokazu, et al.
Publicado: (2014)

The Effect of Particle Size and Surface Roughness of Spray-Dried Bosentan Microparticles on Aerodynamic Performance for Dry Powder Inhalation
por: Kwon, Yong-Bin, et al.
Publicado: (2020)

Retraction: Nafamostat mesylate attenuates the pathophysiologic sequelae of neurovascular ischemia
Publicado: (2021)

Comparative Serum and Brain Pharmacokinetics of Quercetin after Oral and Nasal Administration to Rats as Lyophilized Complexes with β-Cyclodextrin Derivatives and Their Blends with Mannitol/Lecithin Microparticles
por: Manta, Konstantina, et al.
Publicado: (2023)

Preparation and physicochemical characterization of spray-dried and jet-milled microparticles containing bosentan hydrate for dry powder inhalation aerosols
por: Lee, Hyo-Jung, et al.
Publicado: (2016)

Cytokine expressions of spinal cord injury treated by neurotropin and nafamostat mesylate
por: Sun, Chao, et al.
Publicado: (2021)

Optimization of Spray Drying Process Parameters for the Preparation of Inhalable Mannitol-Based Microparticles Using a Box-Behnken Experimental Design
por: Karas, Jakub, et al.
Publicado: (2023)

Development of Nafamostat Mesylate Immediate-Release Tablet by Drug Repositioning Using Quality-by-Design Approach
por: Kim, Hyeon-A, et al.
Publicado: (2022)

Macroporous Mannitol Granules Produced by Spray Drying and Sacrificial Templating
por: Valentin, Morgane, et al.
Publicado: (2022)

Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients
por: Hifumi, Toru, et al.
Publicado: (2020)

Treatment effect of nafamostat mesylate in patients with COVID-19 pneumonia: study protocol for a randomized controlled trial
por: Moon, Kyunglan, et al.
Publicado: (2021)

Dynamic changes in fibrinogen and D-dimer levels in COVID-19 patients on nafamostat mesylate
por: Osawa, Itsuki, et al.
Publicado: (2020)

Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review
por: Hernández-Mitre, María Patricia, et al.
Publicado: (2022)

Application of nafamostat mesylate for anticoagulation in hemoperfusion therapy in patients with bromadiolone poisoning: Case reports
por: Qian, Weiwei, et al.
Publicado: (2023)

Preparation and characterization of microparticles of piroxicam by spray drying and spray chilling methods
por: Dixit, M., et al.
Publicado: (2010)

Nafamostat mesylate-induced hyperkalemia in critically ill patients with COVID-19: Four case reports
por: Okajima, Masaki, et al.
Publicado: (2020)

Clinical efficacy of Nafamostat Mesylate in combination with Favipiravir for COVID-19 pneumonia treatment review article
por: Abduljabbar, Maram H.
Publicado: (2021)

Anaphylactic Reactions Caused by Nafamostat Mesylate during Hemodialysis before Surgery for Carpal Tunnel Syndrome
por: Nakamura, Yuta, et al.
Publicado: (2021)

Nafamostat mesylate prevents metastasis and dissemination of neuroblastoma through vascular endothelial growth factor inhibition
por: Morimoto, Mari, et al.
Publicado: (2022)

Mannitol Is a Good Anticaking Agent for Spray-Dried Hydroxypropyl-Beta-Cyclodextrin Microcapsules
por: Kou, Xingran, et al.
Publicado: (2023)

AN69ST membranes adsorb nafamostat mesylate and affect the management of anticoagulant therapy: a retrospective study
por: Hirayama, Takahiro, et al.
Publicado: (2017)

Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series
por: Doi, Kent, et al.
Publicado: (2020)

Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
por: Hoffmann, Markus, et al.
Publicado: (2020)

Identification of impurities in nafamostat mesylate using HPLC-IT-TOF/MS: A series of double-charged ions
por: Zhang, Yuxin, et al.
Publicado: (2020)

The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications
por: Chen, Xi, et al.
Publicado: (2019)

Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study
por: Kameda, Shinya, et al.
Publicado: (2023)

Inhibition of Listeria Monocytogenes HtrA Protease with Camostat, Gabexate and Nafamostat Mesylates and the Binding Mode of the Inhibitors
por: C, Amrutha M, et al.
Publicado: (2023)

Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics
por: Quinn, Tom M., et al.
Publicado: (2022)

Chitosan Spray-Dried Microparticles for Controlled Delivery of Venlafaxine Hydrochloride
por: Aranaz, Inmaculada, et al.
Publicado: (2017)

Nafamostat mesylate, a serine protease inhibitor, demonstrates novel antimicrobial properties and effectiveness in Chlamydia-induced arthritis
por: Inman, Robert D, et al.
Publicado: (2012)

Association between Nafamostat Mesylate and In-Hospital Mortality in Patients with Coronavirus Disease 2019: A Multicenter Observational Study
por: Inokuchi, Ryota, et al.
Publicado: (2021)

Correction: Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study
por: Kameda, Shinya, et al.
Publicado: (2023)

Effect of Lecithin on the Spontaneous Crystallization of Enzymatically Synthesized Short-Chain Amylose Molecules into Spherical Microparticles
por: Letona, Carlos Andres Morales, et al.
Publicado: (2019)

Spray-dried lactose-leucine microparticles for pulmonary delivery of antimycobacterial nanopharmaceuticals
por: Thiyagarajan, Durairaj, et al.
Publicado: (2021)

Nanoporous mannitol carrier prepared by non-organic solvent spray drying technique to enhance the aerosolization performance for dry powder inhalation
por: Peng, Tingting, et al.
Publicado: (2017)

Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate
por: Iwasaka, Sho, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_89ptjmv81nv7qgsf5ltjdaqrco